Valeo Financial Advisors LLC Sells 86 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Valeo Financial Advisors LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 4,262 shares of the medical research company’s stock after selling 86 shares during the period. Valeo Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,217,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. AMF Tjanstepension AB bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth approximately $42,409,000. Creative Planning raised its stake in Thermo Fisher Scientific by 3.1% during the 3rd quarter. Creative Planning now owns 101,174 shares of the medical research company’s stock valued at $62,583,000 after buying an additional 3,072 shares during the last quarter. Good Life Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 35.6% during the 3rd quarter. Good Life Advisors LLC now owns 621 shares of the medical research company’s stock valued at $384,000 after buying an additional 163 shares during the period. Global Retirement Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 2.5% in the third quarter. Global Retirement Partners LLC now owns 3,274 shares of the medical research company’s stock worth $2,025,000 after acquiring an additional 81 shares during the period. Finally, Howard Capital Management Group LLC increased its position in Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after acquiring an additional 286 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the subject of several research reports. Royal Bank of Canada reduced their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Scotiabank increased their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research report on Monday, February 3rd. Wells Fargo & Company upped their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating for the company in a report on Wednesday, October 23rd. Finally, Bernstein Bank raised their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $658.00.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $532.58 on Friday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The stock has a 50 day moving average of $548.51 and a 200 day moving average of $570.52. The firm has a market cap of $203.71 billion, a PE ratio of 32.22, a PEG ratio of 3.18 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has initiated a share buyback plan on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,125 shares of company stock worth $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.